tutorialpoint.org

B.Pharm Lab. Instruction Manuals

Pharmacology I

APHE Anatomy, Physiology, and Health Education

Pharmaceutical Analysis

Pharmacy study material

Bones and Skeleton System

Bone disease (Gout) (Rheumatoid arthritis) (Osteoarthritis) (Osteoporosis)

Cancer and music therapy

Memory of water

3.5.3 Pharmacology I

pills

Lab 9 Determination of anti-oedemic action of a NSAIDs (Aspirin) with the help of Plethysmometer (Cont'd...)

Theory (cont'd...) Therefore, there are several check points to stop the progression of inflammation and to relief the signs and symptoms of inflammation. Researchers can target the phospholipase A2, NF-$\kappa \beta$, COX-2, 5-LOX, TNF-$\alpha$, IL-1, mast cells etc. to inhibit the synthesis or activation of different mediators of inflammation. Based on this concept several selective and non selective COX inhibitors are invented which can relief the symptoms of inflammations. In our experiment we are going to check only anti oedemic effect of a non steroidal anti inflammatory drug (NSAIDs), aspirin, which non selectively blocks COX-1 and COX-2 enzymes and thus exerts it's anti oedemic action, on the swelled paw of rats [Rang et. al., 2007].

Here, we represent the doses of few steroidal and non steroidal anti inflammatory agents in rats.

Table 1. Representation of the doses of different anti inflammatory agents in rats [John et. al., 1994, Adrian et. al., 1998, Swayeh et. al., 2000, Farre et. al., 1986, Azoubel et. al., 2007, Valiollah et. al., 2011]

Drug

Route of administration

Dose

Steroidal anti inflammatory agents

Dexamethazone

Intragastric

3 mg/kg

Fluvoxamine

Intra-peritoneal

50 mg/kg

Non Selective NSAIDs

Indomethacin

Oral

5-10  mg/kg

Ketorolac

Oral

10 mg/kg

Aspirin

Oral or Intra-peritoneal

100 mg/kg

Flurbiprofen

Oral

5-20 mg/kg

Ketoprofen

Oral

5-20 mg/kg

Flurbi-NO

Oral

5-20 mg/kg

Keto-NO

Oral

5-20 mg/kg

Phenylbutazone

Oral

2.5-5 mg/kg

Piroxicam

Oral

2.5-5 mg/kg

Droxicam

Oral

0.25 and 0.5 mg/kg

Selective NSAIDs

Celecoxib

Oral

5-45 mg/kg

Etoricoxib

Oral

3-9 mg/kg


Reference:

[John et. al., 1994] John L W, Brain R, Carla C, Giuseppe C, Novel anti inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rats, Gastroenterology, vol. 107, pp. 173-179, 1994.
[Adrian et. al., 1998] Adrian S, Brigitta M P, Christian S, Peter N, Thomas S, Beatrice F, Fred H, Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats, British Journal of Pharmacology, vol. 123, pp. 795-804, 1998.
[Swayeh et. al., 2000] Swayeh O A, Clifford R H, Soldato P D, Moore P K, A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin, British Journal of Pharmacology, vol. 129, pp. 343-350, 2000.
[Valiollah et. al., 2011] Valiollah H, Hossein S, Mohsen M, Ahmad M, Ardeshir T, Effect of Fluvoxamine on Carrageenan-Induced Paw Edema in Rats Evaluation of the Action Sites, Iranian Journal of Pharmaceutical Research, vol. 10, pp. 611-618, 2011.
[Azoubel et. al., 2007] Azoubel M C F , Menezes A M A, Bezerra D, Oria R B, Ribeiro R A, Brito G A C, Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats, Brazilian Journal of Medical and Biological Research, vol. 40, pp. 117-125, 2007.
[Farre et. al., 1986] Farre A J, Colombo M, Fort M, Gutierrez B, Rodriguez L, Roser R, Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent, vol. 8, pp. 407-22, 1986.

< Prev.Page   1   2   3   4   5   Next page>



    Engineering Tutorial         Phamacology         Blog

Copyright Shovan Bhaumik 2014 - All Rights Reserved www.tutorialpoint.org
Last modified June 2014